163 related articles for article (PubMed ID: 11979865)
21. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
Dammann HG; Burkhardt F
Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1277-82. PubMed ID: 10563540
[TBL] [Abstract][Full Text] [Related]
22. No influence of pantoprazole on the pharmacokinetics of phenytoin.
Middle MV; Müller FO; Schall R; Groenewoud G; Hundt HK; Huber R; Bliesath H; Steinijans VW
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S72-5. PubMed ID: 8793606
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and drug interactions--relevant factors for the choice of a drug.
Zech K; Steinijans VW; Huber R; Kolassa N; Radtke HW
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S3-6. PubMed ID: 8793598
[TBL] [Abstract][Full Text] [Related]
24. Pantoprazole treatment does not invoke anti-inflammatory properties in vivo.
Becker TL; Maróstica M; Ribeiro ML; de Mendonça S; Gambero A; Pedrazzoli J
Int Immunopharmacol; 2004 Aug; 4(8):1051-7. PubMed ID: 15222979
[TBL] [Abstract][Full Text] [Related]
25. Pantoprazole does not interact with nifedipine in man under steady-state conditions.
Bliesath H; Huber R; Steinijans VW; Koch HJ; Kunz K; Wurst W
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S81-5. PubMed ID: 8793608
[TBL] [Abstract][Full Text] [Related]
26. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells.
Yeo M; Kim DK; Kim YB; Oh TY; Lee JE; Cho SW; Kim HC; Hahm KB
Clin Cancer Res; 2004 Dec; 10(24):8687-96. PubMed ID: 15623654
[TBL] [Abstract][Full Text] [Related]
27. Proton pump inhibitors: an update.
Vanderhoff BT; Tahboub RM
Am Fam Physician; 2002 Jul; 66(2):273-80. PubMed ID: 12152963
[TBL] [Abstract][Full Text] [Related]
28. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
[TBL] [Abstract][Full Text] [Related]
29. Lack of pharmacokinetic interaction between pantoprazole and diclofenac.
Bliesath H; Huber R; Steinijans VW; Koch HJ; Wurst W; Mascher H
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S76-80. PubMed ID: 8793607
[TBL] [Abstract][Full Text] [Related]
30. Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
Lorentzon P; Bayati A; Lee H; Andersson K
Ann N Y Acad Sci; 1997 Nov; 834():592-9. PubMed ID: 9405870
[No Abstract] [Full Text] [Related]
31. Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers.
Simon B; Müller P; Hartmann M; Bliesath H; Lühmann R; Huber R; Bohnenkamp W; Wurst W
Z Gastroenterol; 1990 Sep; 28(9):443-7. PubMed ID: 2177296
[TBL] [Abstract][Full Text] [Related]
32. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
Bardhan KD; Cherian P; Bishop AE; Polak JM; Romanska H; Perry MJ; Rowland A; Thompson M; Morris P; Schneider A; Fischer R; Ng W; Lühmann R; McCaldin B
Am J Gastroenterol; 2001 Jun; 96(6):1767-76. PubMed ID: 11419827
[TBL] [Abstract][Full Text] [Related]
33. [Drug interactions. Proton pump inhibitors. 1].
Gleiter CH
Internist (Berl); 1998 Aug; 39(8):874-5. PubMed ID: 9757395
[No Abstract] [Full Text] [Related]
34. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
Nishioka K; Nagao T; Urushidani T
Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
[TBL] [Abstract][Full Text] [Related]
35. Proton pump inhibitors and gastric acid secretion.
Wolfe MM; Welage LS; Sachs G
Am J Gastroenterol; 2001 Dec; 96(12):3467-8. PubMed ID: 11774990
[No Abstract] [Full Text] [Related]
36. Pantoprazole.
Poole P
Am J Health Syst Pharm; 2001 Jun; 58(11):999-1008. PubMed ID: 11402494
[TBL] [Abstract][Full Text] [Related]
37. Reduction of pentagastrin stimulated acid output: a suitable method to predict efficacy of an irreversible proton pump inhibitor in peptic ulcer disease?
Bliesath H; Simon B; Hartmann M; Müller P; Schneider A; Lühmann R; Wurst W
Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):439. PubMed ID: 1337063
[No Abstract] [Full Text] [Related]
38. [2 new proton pump inhibitors. Possibilities of pantoprazole and lansoprazole].
Leonhardt U; Ritzel U; Ramadori G
Internist (Berl); 1996 Sep; 37(9):944-9; discussion 949. PubMed ID: 8964694
[No Abstract] [Full Text] [Related]
39. Pantoprazole does not interact with the pharmacokinetics of carbamazepine.
Huber R; Bliesath H; Hartmann M; Steinijans VW; Koch H; Mascher H; Wurst W
Int J Clin Pharmacol Ther; 1998 Oct; 36(10):521-4. PubMed ID: 9799054
[TBL] [Abstract][Full Text] [Related]
40. Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction.
De Mey C; Meineke I; Steinijans VW; Huber R; Hartmann M; Bliesath H; Wurst W
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S58-66. PubMed ID: 8793604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
